vs
EXACT SCIENCES CORP（EXAS）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
Sunrun Inc.的季度营收约是EXACT SCIENCES CORP的1.3倍（$1.2B vs $878.4M），Sunrun Inc.净利率更高（8.9% vs -9.8%，领先18.7%），Sunrun Inc.同比增速更快（123.5% vs 23.1%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
EXAS vs RUN — 直观对比
营收规模更大
RUN
是对方的1.3倍
$878.4M
营收增速更快
RUN
高出100.4%
23.1%
净利率更高
RUN
高出18.7%
-9.8%
两年增速更快
RUN
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $103.6M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 8.4% |
| 净利率 | -9.8% | 8.9% |
| 营收同比 | 23.1% | 123.5% |
| 净利润同比 | 90.1% | 103.7% |
| 每股收益（稀释后） | $-0.45 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRUN
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $724.6M | ||
| Q2 25 | $811.1M | $569.3M | ||
| Q1 25 | $706.8M | $504.3M | ||
| Q4 24 | $713.4M | $518.5M | ||
| Q3 24 | $708.7M | $537.2M | ||
| Q2 24 | $699.3M | $523.9M | ||
| Q1 24 | $637.5M | $458.2M |
净利润EXASRUN
| Q4 25 | $-86.0M | $103.6M | ||
| Q3 25 | $-19.6M | $16.6M | ||
| Q2 25 | $-1.2M | $279.8M | ||
| Q1 25 | $-101.2M | $50.0M | ||
| Q4 24 | $-864.6M | $-2.8B | ||
| Q3 24 | $-38.2M | $-83.8M | ||
| Q2 24 | $-15.8M | $139.1M | ||
| Q1 24 | $-110.2M | $-87.8M |
毛利率EXASRUN
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASRUN
| Q4 25 | -9.4% | 8.4% | ||
| Q3 25 | -3.0% | 0.5% | ||
| Q2 25 | -0.3% | -19.7% | ||
| Q1 25 | -13.6% | -22.8% | ||
| Q4 24 | -122.8% | -628.0% | ||
| Q3 24 | -5.6% | -23.8% | ||
| Q2 24 | -3.8% | -24.4% | ||
| Q1 24 | -16.7% | -40.0% |
净利率EXASRUN
| Q4 25 | -9.8% | 8.9% | ||
| Q3 25 | -2.3% | 2.3% | ||
| Q2 25 | -0.1% | 49.1% | ||
| Q1 25 | -14.3% | 9.9% | ||
| Q4 24 | -121.2% | -542.7% | ||
| Q3 24 | -5.4% | -15.6% | ||
| Q2 24 | -2.3% | 26.5% | ||
| Q1 24 | -17.3% | -19.2% |
每股收益（稀释后）EXASRUN
| Q4 25 | $-0.45 | $0.38 | ||
| Q3 25 | $-0.10 | $0.06 | ||
| Q2 25 | $-0.01 | $1.07 | ||
| Q1 25 | $-0.54 | $0.20 | ||
| Q4 24 | $-4.69 | $-12.59 | ||
| Q3 24 | $-0.21 | $-0.37 | ||
| Q2 24 | $-0.09 | $0.55 | ||
| Q1 24 | $-0.60 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | $14.7B |
| 股东权益账面价值 | $2.4B | $3.1B |
| 总资产 | $5.9B | $22.6B |
| 负债/权益比越低杠杆越低 | — | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资EXASRUN
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
总债务EXASRUN
| Q4 25 | — | $14.7B | ||
| Q3 25 | — | $14.6B | ||
| Q2 25 | — | $14.0B | ||
| Q1 25 | — | $13.6B | ||
| Q4 24 | — | $12.9B | ||
| Q3 24 | — | $12.5B | ||
| Q2 24 | — | $12.0B | ||
| Q1 24 | — | $11.1B |
股东权益EXASRUN
| Q4 25 | $2.4B | $3.1B | ||
| Q3 25 | $2.5B | $3.0B | ||
| Q2 25 | $2.5B | $2.9B | ||
| Q1 25 | $2.4B | $2.6B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $3.2B | $5.3B | ||
| Q2 24 | $3.2B | $5.4B | ||
| Q1 24 | $3.1B | $5.2B |
总资产EXASRUN
| Q4 25 | $5.9B | $22.6B | ||
| Q3 25 | $5.9B | $22.2B | ||
| Q2 25 | $5.8B | $21.2B | ||
| Q1 25 | $5.7B | $20.4B | ||
| Q4 24 | $5.9B | $19.9B | ||
| Q3 24 | $6.7B | $22.1B | ||
| Q2 24 | $6.7B | $21.4B | ||
| Q1 24 | $6.4B | $20.8B |
负债/权益比EXASRUN
| Q4 25 | — | 4.69× | ||
| Q3 25 | — | 4.90× | ||
| Q2 25 | — | 4.80× | ||
| Q1 25 | — | 5.19× | ||
| Q4 24 | — | 5.05× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | 2.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $96.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.94× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRUN
| Q4 25 | $151.7M | $96.9M | ||
| Q3 25 | $219.9M | $-121.5M | ||
| Q2 25 | $89.0M | $-292.7M | ||
| Q1 25 | $30.8M | $-104.2M | ||
| Q4 24 | $47.1M | $-258.4M | ||
| Q3 24 | $138.7M | $-156.2M | ||
| Q2 24 | $107.1M | $-208.5M | ||
| Q1 24 | $-82.3M | $-143.1M |
自由现金流EXASRUN
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $-156.4M | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASRUN
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | -29.1% | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASRUN
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 0.0% | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASRUN
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | -7.33× | ||
| Q2 25 | — | -1.05× | ||
| Q1 25 | — | -2.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.50× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
